Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. Online ahead of print.
No abstract available